Incidence of Venous Thromboembolism and Professional Practices in Brest Area

The aim of this study estimate VTE incidence. Investigators prospectively record all cases of symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) of the lower limbs diagnosed between March 1, 2013 and February 28, 2014 in hospitals and in the community.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Embolism and Thrombosis Thromboembolism Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) diagnosis confirmed
Patient living in Brest area from time of diagnosis

Exclusion criteria

invalid diagnosis
asymptomatic event
Main residence patient out of Brest area.

Treatment and study plan

Primary outcomes

Gathering information about potential factors predisposing Thromboembolic disease and treatments undertaken.

Time frame: two years after VTE

After two years, all medication given to the patient to treat his initial VTE will be recorded, as well as the ongoing of thromboembolic disease

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: EPIGETBO III

Important dates

Study start: 2013
Primary completion: 2017
Study completion: 2017
First posted: Sep 12, 2016
Registry last updated: Jul 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed